CCTA continues to grow more and more important in the day-to-day treatment of heart patients. Hospitals and health systems that fail to embrace the modality risk falling behind.
Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.